enGene Therapeutics

ENGN on Nasdaq. Biological products, (no diagnostic substances). Market value $162m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to July 2026. Quality checks use five annual reports, the latest for the year to October 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to July 2026
-89.2%low

For every $100 of what the whole company costs, it produced $-89.18 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to July 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to October 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$1.74 a share, 24% above its 1-year low

Over the past year the price has ranged from $1.40 to $12.25.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.0
-0.1
-0.1
20232024202512 monthsto Jul '26
Revenue
n/an/an/a
Operating margin
n/an/an/a
Debt to equity
n/an/an/a
Shares outstanding
0.04bn0.05bn0.07bn

Health checks

  • Free cash flow positive0 of 3 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 52% more shares since 2023

The quarter to July 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $33 million, compared with a loss of $29 million a year ago.
  • Over the past 12 months it spent $104 million more cash than it brought in, compared with $95 million a year earlier.
  • 36% more shares than a year ago. Each share owns a bit less of the company.
Profit by quarter
Profit by quarter
Quarter toAmount
October 2024-$15m
January 2025-$25m
April 2025-$26m
July 2025-$29m
October 2025-$38m
January 2026-$30m
April 2026-$30m
July 2026-$33m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
22 December 2025
Next quarterly (estimated, 10-Q)
8 December 2026

Who owns it

None of the long-term investors we follow own it. 56 funds in all.

Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

8 investors own more than 5%.

  • BML Investment Partners, L.P.
    Passive investor
    9.9%+2.1 pts
    Since 12 May 2026
  • Raymond Debbane
    Passive investor
    at least 9.3%+1.5 pts
    (filed with 7 related holders)
    Since 30 June 2026
  • Perceptive Advisors LLC
    Passive investor
    at least 8.9%−1.1 pts
    (filed with 2 related holders)
    Since 30 September 2026
  • at least 5.1%
    (filed with 2 related holders)
    Since 30 September 2026
  • Anders Hove
    Passive investor
    at least 5.0%
    (filed with 4 related holders)
    Since 20 July 2026
  • Adage Capital Management, L.P.
    Passive investor
    at least 3.0%
    (filed with 2 related holders)
    Since 31 December 2024
  • at least 2.2%−7.6 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • BVF PARTNERS L P/IL
    Passive investor
    at least 1.8%−4.1 pts
    (filed with 9 related holders)
    Since 27 January 2025
  • Sold down below 5%
    Since 30 June 2026
  • Deep Track Capital, LP
    Passive investor
    Sold down below 5%
    Since 30 June 2026
  • Venrock Healthcare Capital Partners III, L.P.
    Passive investor
    Sold down below 5%
    Since 30 June 2026
  • Sold down below 5%
    Since 31 March 2026
  • Foresite Capital Fund VI, L.P.
    Passive investor
    Sold down below 5%
    Since 30 September 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $10,051 of shares on the open market.

  • Grossman William
    Interim Chief Medical Officer, Director
    Bought
    Date
    22 September 2026
    Shares
    5,102
    Price
    $1.97
    Value
    $10,051

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 22 Dec 2025, plus the 10-Q filed 8 Sep 2026 and 13 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.